BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $9.75 Consensus Price Target from Analysts

Share on StockTwits

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned a consensus rating of “Hold” from the ten ratings firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $9.75.

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, October 31st. Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 6th. BidaskClub lowered BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, October 4th. ValuEngine lowered BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Finally, Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th.

BioCryst Pharmaceuticals stock traded down $0.02 during trading hours on Monday, hitting $1.58. The stock had a trading volume of 15,182,200 shares, compared to its average volume of 1,549,563. The company has a 50-day moving average of $2.41 and a two-hundred day moving average of $3.56. The company has a quick ratio of 1.43, a current ratio of 1.44 and a debt-to-equity ratio of 2.38. The company has a market cap of $210.94 million, a PE ratio of -1.61 and a beta of 1.86. BioCryst Pharmaceuticals has a fifty-two week low of $1.38 and a fifty-two week high of $9.95.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03). The firm had revenue of $1.78 million during the quarter, compared to analyst estimates of $4.54 million. BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 641.29%. As a group, analysts forecast that BioCryst Pharmaceuticals will post -1.25 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can grew its position in BioCryst Pharmaceuticals by 921.9% during the 2nd quarter. Bank of Montreal Can now owns 10,219 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 9,219 shares during the last quarter. Quantamental Technologies LLC bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $43,000. Jane Street Group LLC bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $69,000. Cubist Systematic Strategies LLC grew its position in BioCryst Pharmaceuticals by 143.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 27,016 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 15,924 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC grew its position in BioCryst Pharmaceuticals by 297.3% during the 2nd quarter. Quantitative Systematic Strategies LLC now owns 43,590 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 32,618 shares during the last quarter. Institutional investors own 90.62% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

See Also: What is a good dividend yield?

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hanover Insurance Group  Sets New 12-Month High at $137.58
Hanover Insurance Group Sets New 12-Month High at $137.58
GlobalToken  Price Hits $0.0005 on Top Exchanges
GlobalToken Price Hits $0.0005 on Top Exchanges
Bonpay Price Down 0.4% Over Last 7 Days
Bonpay Price Down 0.4% Over Last 7 Days
Paypex Trading Up 0.8% Over Last Week
Paypex Trading Up 0.8% Over Last Week
AdultChain 1-Day Volume Tops $1.00
AdultChain 1-Day Volume Tops $1.00
Integra Resources  Given a C$2.50 Price Target by Raymond James Analysts
Integra Resources Given a C$2.50 Price Target by Raymond James Analysts


 
© 2006-2019 Zolmax.